Newron Pharmaceuticals
Newron Pharmaceuticals SpA: Expanding Global and U.S. Investor & Partner Visibility
Investor Relations
The change they wanted
- Newron is a Swiss-traded biopharmaceutical company focused on therapies for patients with diseases of the central nervous system.
- Promote new breakthrough data supporting that evenamide for schizophrenia impacts long-term brain plasticity changes in its long-term therapeutic actions.
- Build global visibility and expand understanding with sell-side analysts, potential partners/licensees, investors, and the investment banking community.
What we did
- Execute a globally viewed scientific and investor-oriented R&D Day to increase investor and partner visibility.
- Develop a US-centric marketing strategy for the event, including message and presentation development, event and location branding, and broadcast.
- Audience acquisition through extensive media relations, press release distribution, focused email campaigns, and personal investor and partner outreach.
The change we delivered
- Secured the participation of the world’s leading experts in neurobiology, psychiatry, and schizophrenia as speakers.
- Live video of three leading schizophrenia KOL experts, elevating Newron’s presence and market shaping
- 35 in-person attendees, including representatives from 5 investment banks and 9 sell-side analysts.
- More than 200 live webcast participants from 7 countries worldwide.
- Global webcast of event listened to for more than 700 total hours in more than 400 live and on-demand sessions